US2014017240A1PendingUtilityA1

Fully Human Antibodies Against N-Cadherin

52
Assignee: UNIV CALIFORNIAPriority: Nov 10, 2008Filed: Jun 17, 2013Published: Jan 16, 2014
Est. expiryNov 10, 2028(~2.3 yrs left)· nominal 20-yr term from priority
Inventors:Robert E. ReiterEric J. LepinAnna M. Wu
C07K 16/2896A61K 2039/505G01N 2333/70525C07K 2317/622A61P 35/04C07K 2317/21A61K 39/3955G01N 33/57555G01N 33/5758G01N 33/575C07K 16/18A61K 39/395C12N 15/11A61P 35/00G01N 33/574
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.

Claims

exact text as granted — not AI-modified
1 . A monoclonal antibody or fragment thereof capable of binding to extracellular domain 4 of N-cadherin, comprising the amino acid sequence of SEQ ID NO: 1. 
     
     
         2 . The antibody of  claim 1 , wherein the fragment is a scFv. 
     
     
         3 . The antibody of  claim 1 , wherein the fragment is a diabody. 
     
     
         4 . A monoclonal antibody or fragment thereof capable of binding to extracellular domain 1-3 of N-cadherin, comprising the amino acid sequence of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, or 9. 
     
     
         5 . The antibody of  claim 4 , wherein the fragment is a scFv. 
     
     
         6 . The antibody of  claim 4 , wherein the fragment is a diabody. 
     
     
         7 . A method of treating a cancer patient, comprising the steps of:
 (a) obtaining a test tissue sample from an individual at risk of having a cancer that expresses a N-cadherin protein;   (b) determining the presence or absence or amount of the N-cadherin protein in the test tissue sample in comparison to a control tissue sample from an individual known to be negative for the cancer; thereby diagnosing said cancer that expresses a N-cadherin protein, wherein the N-cadherin protein is expressed at normal or low levels, or is expressed by a subset of cells, or is overexpressed; and   (c) administering an effective amount of N-cadherin antibody or fragment of  claim 1  or  4  to the individual at risk of having a cancer that expresses a N-Cadherin protein.   
     
     
         8 . The method of  claim 7 , wherein said tissue sample is prostate or bladder tissue. 
     
     
         9 . The method of  claim 7 , wherein said cancer is a prostate cancer. 
     
     
         10 . The method of  claim 7 , wherein said cancer is a bladder cancer. 
     
     
         11 . The method of  claim 7 , wherein said cancer is a hormone refractory prostate cancer. 
     
     
         12 . The method of  claim 7 , wherein said antibody blocks hormone refractory prostate cancer. 
     
     
         13 . The method of  claim 7 , wherein said antibody blocks cancer stem cells. 
     
     
         14 . The method of  claim 7 , wherein said cancer is a metastatic cancer. 
     
     
         15 . The method of  claim 7 , wherein said antibody is a monoclonal antibody. 
     
     
         16 . The method of  claim 7 , wherein the antibody is a scFv. 
     
     
         17 . The method of  claim 7 , wherein the antibody is a diabody. 
     
     
         18 . A method of diagnosing a cancer patient, comprising the steps of:
 (a) obtaining a test tissue sample from an individual at risk of having a cancer that expresses a N-cadherin protein;   (b) determining the presence or absence or amount of the N-cadherin protein in the test tissue sample in comparison to a control tissue sample from an individual known to be negative for the cancer by contacting a sample with an effective amount of N-cadherin antibody or fragment of  claim 1 ; thereby diagnosing said cancer that expresses a N-cadherin protein, wherein the N-cadherin protein is expressed at normal or low levels, or is expressed by a subset of cells, or is overexpressed.   
     
     
         19 . A method of identifying cancer stem cells, comprising the steps of:
 (a) obtaining a test tissue sample from an individual at risk of having a cancer that expresses a N-cadherin protein;   (b) determining the presence or absence of cancer stem cells in the test tissue sample in comparison to a control tissue sample from an individual known to be negative for the cancer; wherein the N-cadherin protein is expressed at normal or low levels, or is expressed by a subset of the stem cells and is not overexpressed, using the antibodies of  claim 1 .   
     
     
         20 . The method of  claim 19 , wherein said tissue sample is prostate or bladder tissue. 
     
     
         21 . The method of  claim 19 , wherein said cancer is a prostate cancer. 
     
     
         22 . The method of  claim 19 , wherein said cancer is a bladder cancer. 
     
     
         23 . The method of  claim 19 , wherein said cancer is a hormone refractory prostate cancer. 
     
     
         24 . The method of  claim 19 , wherein said cancer is a metastatic cancer. 
     
     
         25 . An isolated nucleic acid comprising a nucleotide sequence encoding a sequence of  claim 1 . 
     
     
         26 . An isolated vector comprising the nucleic acid of  claim 25 . 
     
     
         27 . A host cell comprising the vector of  claim 26 .

Join the waitlist — get patent alerts

Track US2014017240A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.